PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20032260-4	2010	Treatment of endothelial cells (EC) with VEGF stimulated eNOS phosphorylation and cGMP accumulation; pretreatment with the sGC inhibitor 4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one (NS-2028) blunted cGMP levels without affecting VEGF-receptor phosphorylation.	NS 2028	197-204	vascular endothelial growth factor A	Oryctolagus cuniculus	41-45	
20032260-0	2010	The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability.	NS 2028	39-46	vascular endothelial growth factor A	Oryctolagus cuniculus	55-89	
20032260-5	2010	Incubation of cells with NS-2028 blocked the mitogenic effects of VEGF.	NS 2028	25-32	vascular endothelial growth factor A	Oryctolagus cuniculus	66-70	
20032260-12	2010	Animals receiving NS-2028 orally displayed a reduced angiogenic response to VEGF.	NS 2028	18-25	vascular endothelial growth factor A	Oryctolagus cuniculus	76-80	
20032260-14	2010	Using a modified Miles assay, we observed that NS-2028 attenuated VEGF-induced permeability.	NS 2028	47-54	vascular endothelial growth factor A	Oryctolagus cuniculus	66-70